Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6711139 | 0.87 | MAPT (0.59) | MAPTNAMPTALDH1A1LMNAHTT | |
| SCHEMBL6709636 | 0.81 | NAMPT (0.39) | MAPTNAMPTALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL6715237 | 0.76 | MAPT (0.56) | MAPTALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL6709632 | 0.73 | MAPT (0.48) | MAPTNAMPTALDH1A1HPGDLMNA | |
| SCHEMBL6711133 | 0.69 | MAPT (0.55) | MAPTNAMPTALDH1A1LMNAHTT | |
| SCHEMBL6709643 | 0.69 | MAPT (0.48) | MAPTALDH1A1HPGDLMNAHTT | |
| SCHEMBL6710981 | 0.69 | FNTA (0.49) | MAPT | |
| SCHEMBL6708733 | 0.68 | FNTA (0.45) | — | |
| SCHEMBL6711137 | 0.67 | NAMPT (0.40) | MAPTNAMPTALDH1A1LMNAHTT | |
| SCHEMBL6715004 | 0.67 | FNTA (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092524-A1 | Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same | PIERRE FABRE MEDICAMENT (FR) | 2004-05-13 | — | — | US | disclosed |
| EP-1324999-A1 | NOVEL AMINOPHENYL PIPERAZINE OR AMINOPHENYL PIPERIDINE DERIVATIVES INHIBITING PRENYL TRANSFERASE PROTEINS AND METHODS FOR PREPARING SAME | PIERRE FABRE MEDICAMENT (FR) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002030927-A1 | NOVEL AMINOPHENYL PIPERAZINE OR AMINOPHENYL PIPERIDINE DERIVATIVES INHIBITING PRENYL TRANSFERASE PROTEINS AND METHODS FOR PREPARING SAME | PIERRE FABRE MEDICAMENT (FR) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092524-A1 | Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same | CBR3, CBR1, HCCS | MAPT 4753/4885NAMPT 2590/4885ALDH1A1 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.